Jonathan Yu Chen

US Patent:

20230047290, Feb 16, 2023

Filed:

Aug 6, 2021

Appl. No.:

17/396344

Inventors:

- Lincolnshire IL, US
Venkateswaran Narayanan - Bangalore, IN
Ambika Nagarajaiah - Bangalore, IN
Ohad Shatil - Dunwoody GA, US
Sethuraman Vijayakumar - Madurai, IN
Dayal Madhukar Rai - Bangalore, IN
Alexander Punnamoottil Jacob - Palakkad, IN
Jonathan Chen - Medford NY, US

International Classification:

H04W 24/04
H04W 24/08
H04W 76/10

Abstract:

A computing device includes: a wireless communication interface; and a processor configured to: establish a connection with a wireless network; while a network-layer status of the connection is active, monitor attributes of the connection at the wireless communication interface, the attributes including (i) a number of uplink packets transmitted since a most recent downlink packet was received, and (ii) a time period elapsed since the most recent downlink packet was received; determine that the attributes meet recovery criteria indicative of a network-layer interruption in the wireless network; in response to the determination, control the wireless communication interface to initiate a recovery action to resolve the network-layer interruption.

US Patent:

20150004175, Jan 1, 2015

Filed:

Dec 13, 2012

Appl. No.:

14/364714

Inventors:

- NEW HAVEN CT, US
Jonathan Chen - Barrington IL, US

International Classification:

A61K 39/395
A61K 31/7088
A61K 38/02

US Classification:

4241581, 514 11, 514 37, 514 38, 514 43, 514 193, 514 44 R, 514 44 A

Abstract:

The compositions and methods described herein are useful for diminishing CTL exhaustion in a subject in need thereof, during an immune response to a viral infection or during an immune response to cancer, thereby leading to a greater CTL response against the viral infection or cancer. The invention relates to compositions and methods for the therapeutic intervention of signaling through EP2 and EP4, by inhibiting at least one of EP2, EP4, PGE2, or combinations thereof. The invention also relates to compositions and methods for the therapeutic intervention of signaling through EP2 and EP4, in combination with the therapeutic intervention of signaling through PD-1, by inhibiting at least one of EP2, EP4, PGE2, or combinations thereof, in combination with inhibiting at least one of PD-1, PD-L1, PD-L2, and combinations thereof.